Please use this identifier to cite or link to this item:
Title: PSMA PET-CT imaging predicts treatment progression in men with biochemically recurrent prostate cancer—a prospective study of men with 3 year follow up.
Epworth Authors: Ong, Sean
Pascoe, Claire
Webb, David
Bolton, Damien
Murphy, Declan
Bowden, Patrick
Lawrentschuk, Nathan
Other Authors: Kelly, Brian
Ballok, Zita
Sengupta, Shomik
Keywords: Prostate-Specific Membrane Antigen
positron emission Tomography-Computed Tomography
Prostate Cancer
EJ Whitten Foundation Prostate Cancer Research Centre at Epworth, Melbourne, Australia
UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Jun-2022
Publisher: MDPI
Citation: Cancers (Basel). 2022 Jun; 14(11): 2717
Abstract: Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) is a novel imaging modality used to stage recurrent prostate cancer. It has the potential to improve prognostication and ultimately guide the timing of treatment for men with recurrent prostate cancer. This study aims to assess the clinical impact of PSMA PET-CT by analyzing its predictive value of treatment progression after 3 years of follow-up. In this prospective cohort study of 100 men, patients received a PSMA PET-CT for restaging of their disease which was used by a multi-disciplinary team to make a treatment decision. The primary endpoint was treatment progression. This was defined as the addition or change of any treatment modalities such as androgen deprivation therapy (ADT), radiation therapy or chemotherapy. The median follow-up time was 36 months (IQR 24–40 months). No treatment progression was found in 72 (75%) men and therefore 24 (25%) patients were found to have treatment progression. In men with a negative PSMA PET-CT result, 5/33 (15.1%) had treatment progression and 28/33 (84.8%) had no treatment progression. In conclusion, clinical decisions made with PSMA PET-CT results led to 75% of men having no treatment progression at 3 years of follow-up. In men with negative PSMA PET-CT results, this increased to 85% of men
DOI: 10.3390/cancers14112717
PubMed URL:
ISSN: 2072-6694
Journal Title: Cancers (Basel)
Type: Journal Article
Affiliated Organisations: Young Urology Researcher’s Organisation, Melbourne, VIC 3000, Australia
Department of Surgery, University of Melbourne, Parkville, VIC 3010, Australia
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
Department of Urology, Eastern Health, Box Hill, VIC 3128, Australia
Department of Nuclear Medicine, Richmond Medical Imaging, Richmond, VIC 3121, Australia
Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, VIC 3084, Australia
Eastern Health Clinical School, Monash University, Box Hill, VIC 3128, Australia
Department of Urology, Royal Melbourne Hospital, Melbourne, VIC 3051, Australia
Type of Clinical Study or Trial: Prospective Cohort Study
Appears in Collections:Cancer Services
UroRenal, Vascular

Files in This Item:
There are no files associated with this item.

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.